
<html>

<head>





</head>

<body lang="EN-US" link="blue" vlink="purple">

<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="252" height="91" src="g153571mmimage002.jpg"></font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PRESS
RELEASE</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contacts:</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investors/Media:</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Kevin C. O&#146;Boyle</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stephanie Carrington/Greg Tiberend</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Chief Financial Officer</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Ruth Group</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NuVasive,
  Inc.</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">646-536-7017/7005</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">858-271-7070</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">scarrington@theruthgroup.com</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">investorrelations@nuvasive.com</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">gtiberend@theruthgroup.com</font></p>
  </td>
 </tr>
</table>

<p align="center" style="font-size:10.0pt;font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font face="Times New Roman">&nbsp;</font></b></p>

<p align="center" style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">NuVasive Announces Executive Promotions</font></b></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">San
Diego, CA &#151; December 22, 2004</font></b> &#151; NuVasive, Inc.
(Nasdaq: NUVA), a medical device company focused on developing products for
minimally disruptive surgical treatments for the spine, announced today the
following executive promotions, effective December 17, 2004:</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Keith Valentine
promoted to President</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Kevin O&#146;Boyle
promoted to Executive Vice President and Chief Financial Officer</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pat Miles
promoted to Senior Vice President of Marketing</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Jonathan
Spangler promoted to Vice President and Chief Patent Counsel</p>

<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In conjunction with these
promotions Alexis V. Lukianov&#146;s title is now Chairman of the Board and Chief
Executive Officer.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alexis V. Lukianov, Chairman
and Chief Executive Officer, remarked, &#147;All four of these individuals have
repeatedly demonstrated their dedication, commitment and drive to achieve
outstanding results. They have been instrumental in driving the progress of our
strategy to expand market penetration of our leading spine surgery products and
technologies. I am proud of their many successes, passion and determination to
meet customer and business needs and I am confident that they will continue to
provide the same level of support and dedication to the growth of our Company.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;The promotion of Keith
Valentine is significant since it recognizes the responsibilities that Keith
has already assumed over the last year, working along side me and the NuVasive
team to implement our growth strategy.&#160;
Kevin O&#146;Boyle&#146;s promotion is equally meaningful since it recognizes his
continued responsibilities in working closely with me to manage finance and
operations.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Keith
Valentine</font></b> has served as Executive Vice President of
NuVasive since January&nbsp;2002 and as Senior Vice President of Marketing
&amp; Development since January 2001. Mr. Valentine&#146;s responsibilities include
R&amp;D, regulatory and clinical affairs, quality assurance, marketing,
customer service, distribution and legal patent matters. Prior to joining
NuVasive, he served as</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kr\04-15357-1\task263700\15357-1-mm.htm',USER='kranganathan',CD='Dec 28 19:32 2004' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President of Marketing at
ORATEC Interventions,&nbsp;Inc., a medical device company that was acquired by
Smith&nbsp;&amp; Nephew plc. He also served in various capacities at Medtronic
Sofamor Danek, including Vice President of Marketing for the Rods Division and
Group Director for the BMP Biologics program, the Interbody Sales Development
effort and International Sales and Marketing. Mr.&nbsp;Valentine received a
B.B.A. in Management and Biomedical Sciences from Western Michigan University.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Kevin
O&#146;Boyle</font></b> has served as NuVasive&#146;s Senior Vice President
and Chief Financial Officer since January&nbsp;2003. Mr. O&#146;Boyle&#146;s
responsibilities include finance and accounting, operations, information
technology and investor relations. Prior to joining NuVasive, he served as
Chief Financial Officer and Chief Operating Officer at ChromaVision Medical
Systems,&nbsp;Inc., a publicly traded medical device firm specializing in the
oncology market. Prior to joining ChromaVision, he was Chief Financial Officer
and Senior Vice President of Operations at Albert Fisher North
America,&nbsp;Inc., a publicly traded international food company. Mr.&nbsp;O&#146;Boyle
is a CPA and received a B.S. in Accounting from the Rochester Institute of
Technology and completed the Executive Management Program at the University of
California at Los Angeles John E. Anderson Graduate Business School.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Pat
Miles</font></b> has been Vice President of Marketing at NuVasive
since April of 2002 and Group Director of Neurophysiologic Marketing since
January of 2001. Mr. Miles has recently established new departments to focus on
medical and surgeon education and corporate projects. Prior to joining
NuVasive, he served as Director of Marketing for ORATEC
Interventions,&nbsp;Inc., a medical device company. Prior to that, he served as
Director of Marketing for Minimally Invasive Systems and Cervical Spine Systems
for Medtronic Sofamor Danek. He also served in several sales and marketing
capacities at Smith and Nephew Orthopaedics, a global orthopaedic implant and
instrument manufacturing company from 1992-1997.&#160; Mr.&nbsp;Miles received a B.S. in Finance
from Mercer University.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Spangler</font></b> has been Chief Patent Counsel and Group
Director of Intellectual Property at NuVasive since September&nbsp;2001. Prior
to joining NuVasive, he served as Chief Patent Counsel for A-Med
Systems,&nbsp;Inc., a privately held medical technology company. Prior to that,
he practiced law at Arnold White&nbsp;&amp; Durkee, specializing in patent and
trade secret litigation involving medical devices and at Haugen&nbsp;&amp;
Nikolai, specializing in patent prosecution involving medical devices.
Mr.&nbsp;Spangler is licensed to practice law in the States of California and
Minnesota and before the U.S. Trademark Office.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h2 style="font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-decoration:underline;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">About NuVasive</font></u></h2>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NuVasive is a medical device<b><font style="font-weight:bold;"> </font></b>company focusing on the design, development and marketing
of products for use in minimally disruptive surgical treatments for the spine.
NuVasive&#146;s Maximum Access Surgery (MAS&#153;) product platform includes the
NeuroVision&#174; nerve avoidance system, MaXcess&#153; spine access system, and
specialized implants.&#160; NuVasive also
offers classic fusion implant products for use in spine surgery and has an
R&amp;D pipeline emphasizing motion preservation products such as total disc
replacement (TDR).</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kr\04-15357-1\task263700\15357-1-mm.htm',USER='kranganathan',CD='Dec 28 19:32 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could cause
NuVasive&#146;s results to differ materially from historical results or those
expressed or implied by such forward-looking statements.&#160; All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including statements containing the words &#147;planned,&#148; &#147;expects,&#148; &#147;believes,&#148;
&#147;strategy,&#148; &#147;opportunity,&#148; &#147;anticipates&#148; and similar words.&#160; These statements may include, among others,
plans, strategies and objectives of management for future operations; any
statements regarding proposed new products, services or developments; any statements
regarding future economic conditions or financial or operating performance;
statements of belief and any statements of assumptions underlying any of the
foregoing. The potential risks and uncertainties that could cause actual growth
and results to differ materially include, but are not limited to, the rapidly
changing and competitive nature of the medical device industry, NuVasive&#146;s
ability to convince surgeons to use its products, the ability of patients to
obtain third-party reimbursement for surgical procedures employing NuVasive&#146;s
products, risks related to government regulation of medical devices, risks
related to NuVasive&#146;s ability to effectively manage the growth of its business,
risks related to ownership and enforcement of intellectual property rights,
NuVasive&#146;s ability to successfully develop new products, and other risks and
uncertainties more fully described in NuVasive&#146;s Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission and NuVasive&#146;s Prospectus
filed pursuant to Rule 424 under the Securities Act of 1933, as amended, with
the Securities and Exchange Commission on May 13, 2004.&#160; NuVasive&#146;s public filings with the Securities
and Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events or
circumstances arising after the date on which it was made.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">#&#160;&#160; #&#160;&#160; #</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kr\04-15357-1\task263700\15357-1-mm.htm',USER='kranganathan',CD='Dec 28 19:32 2004' -->


</body>

</html>

